Wedbush Expects Higher Earnings for Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities researchers at Wedbush boosted their FY2025 earnings per share estimates for Zentalis Pharmaceuticals in a research note issued to investors on Tuesday, November 11th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($1.68) for the year, up from their previous estimate of ($1.81). Wedbush currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2025 earnings at ($0.31) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at ($0.41) EPS and FY2029 earnings at $0.08 EPS.

ZNTL has been the subject of a number of other reports. Wall Street Zen cut Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Morgan Stanley cut their price target on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 7th. Leerink Partners reissued a “market perform” rating and issued a $2.00 target price on shares of Zentalis Pharmaceuticals in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $5.03.

Zentalis Pharmaceuticals Stock Down 4.3%

Zentalis Pharmaceuticals stock opened at $1.34 on Thursday. Zentalis Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $4.44. The business has a fifty day moving average of $1.54 and a two-hundred day moving average of $1.45. The firm has a market cap of $96.66 million, a P/E ratio of -0.65 and a beta of 1.87.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.12.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently modified their holdings of ZNTL. Millennium Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after purchasing an additional 2,111,951 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Zentalis Pharmaceuticals by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after buying an additional 19,768 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Zentalis Pharmaceuticals by 4.7% during the 2nd quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company’s stock worth $3,241,000 after buying an additional 124,985 shares during the period. Almitas Capital LLC raised its stake in shares of Zentalis Pharmaceuticals by 5.2% during the 1st quarter. Almitas Capital LLC now owns 1,710,921 shares of the company’s stock worth $2,720,000 after buying an additional 84,025 shares during the period. Finally, Tybourne Capital Management HK Ltd. lifted its position in shares of Zentalis Pharmaceuticals by 53.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock valued at $1,715,000 after buying an additional 516,666 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.